The FDA delays its decision on Biogen's controversial pitch on its Alzheimer's drug — and the biotech's shares soar
Usually, a 3-month delay on a PDUFA deadline is unwelcome news at a biopharma company. For Biogen $BIIB, it’s manna from heaven.
The big biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
